Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Islatravir + Doravirine + Lamivudine in Treatment-Naïve HIV-1
NCT03272347Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Nov 2017
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial of islatravir in human immunodeficiency virus type 1 infection (HIV-1) (4 arms), sponsored by Merck & Co. Primary endpoints: Percentage of Participants With HIV-1 RNA <50 Copies/mL at Week 24, Percentage of Participants With HIV-1 RNA <50 Copies/mL at Week 48 and 2 more. Started Nov 2017; status: completed.
02
Drugs
islatravir
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT03272347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03272347.